OCULAR THERAPEUTIX INC (OCUL)
Health Care · NASDAQ
Ocular Therapeutix is a biopharmaceutical company leveraging proprietary bioresorbable hydrogel technology to deliver retinal therapies, with AXPAXLI (axitinib) in Phase 3 for wet AMD and diabetic retinal disease, and commercial product DEXTENZA approved for post-surgical inflammation and allergic conjunctivitis.
What OCULAR THERAPEUTIX INC does
Ocular Therapeutix is an integrated biopharmaceutical company focused on retinal diseases, with a proprietary ELUTYX bioresorbable hydrogel-based formulation technology that enables prolonged local drug delivery to the eye. The company's lead candidate AXPAXLI (axitinib) is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), while DEXTENZA, a corticosteroid-eluting intracanalicular insert, is FDA-approved for ocular inflammation, pain following ophthalmic surgery, and allergic conjunctivitis. The ELUTYX platform incorporates previously approved FDA therapeutic agents into bioresorbable hydrogels designed to dissolve safely after drug delivery is complete.
Themes: ["wet AMD (age-related macular degeneration)"]
Fundamentals
- Price$10.54 as of 2026-07-09 close
- Market cap$2.2B as of 2026-07-10
- 1-year return-2.0% as of 2026-07-09 close
- Net margin-558.2% as of 2026-07-10
- Gross margin+87.2% as of 2026-07-10
- ROE-64.5% as of 2026-07-10
- Debt / equity0.12 as of 2026-07-10
- Revenue growth (YoY)-12.7% as of 2026-07-10
- Revenue CAGR (3y)+0.3% SEC XBRL
- Beta0.91 as of 2026-07-10
Key risks (from latest filing)
["AXPAXLI is still in Phase 3 clinical trials; failure to achieve primary efficacy endpoints in SOL-1, SOL-R, or HELIOS-3 trials could delay or prevent regulatory approval and market entry, directly impacting the company's future revenue and viability."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.